Effect of Thymalin on the Tumor and Thymus under Conditions of Activation Therapy In Vivo.

Pronounced antitumor effect of Thymalin in doses lower than the therapeutic doses was shown in experiments on albino outbred male rats with transplanted sarcoma 45. Tumor growth arrest and its regression were observed in more than half of animals and in other cases, the growth was suppressed by 78%. Microstructural changes in the thymus were analyzed. Significant increase in lymphoproliferative activity and the content of tissue basophils and plasmocytes in the thymus lobules was observed. Tumor regression was accompanied by the development of stable antistress adaptation reactions of calm and elevated activation. High efficiency of Thymalin can be attributed to the use of lower doses of the substance and their modulation during the treatment course in accordance with the regimes of activation therapy.

Preclinical murine tumor models: a structural and functional perspective.

The goal of this review is to pinpoint the specific features, including the weaknesses, of various tumor models, and to discuss the reasons why treatments that are efficient in murine tumor models often do not work in clinics. In a detailed comparison of transplanted and spontaneous tumor models, we focus on structure-function relationships in the tumor microenvironment. For instance, the architecture of the vascular tree, which depends on whether tumor cells have gone through epithelial-mesenchymal transition, is determinant for the extension of the spontaneous necrosis, and for the intratumoral localization of the immune infiltrate. Another key point is the model-dependent abundance of TGFß in the tumor, which controls the variable susceptibility of different tumor models to treatments. Grounded in a historical perspective, this review provides a rationale for checking factors that will be key for the transition between preclinical murine models and clinical applications.

[Analysis of related factors of coins foreign bodies crossing the esophagus in 204 cases of children].

Objective:To explore the anti-tumor effect of Stat3 antisense oligodeoxynucleotide on human Hep-2 cell tumor-bearing BALB/c nude mouse, to study the therapeutic value of Stat3 antisense oligodeoxynucleotide on laryngeal cancer. Method:Hep-2 cells from human laryngeal carcinoma in logarithmic phase were inoculated subcutaneously into BALB/c mice to establish a model of human Hep-2 cell tumor-bearing BALB/c mice. They were divided into blank group, control group and different concentrations of AS3 groups(1 group, 2 group, 3 group, 4 group), and then intraperitoneally administered once a day for 4 weeks, measuring body weight twice a week, and the long and short diameters of the tumors were recorded. After 4 weeks, the mice in each group were weighted. The subcutaneous transplanted tumors were dissected, weighted, and inhibitory rate was obtained.Result:Stat3 antisense oligodeoxynucleotide can obviously inhibited the growth of human Hep-2 cell tumor-bearing BALB/c mice with the concentration of antisense oligodeoxynucleotide heightened. The IR in different concentration AS3 groups was obviously higher than that in the control group(P<0.01) .Conclusion:Stat3 antisense oligodeoxynucleotide can obviously inhibit the growth of subcutaneous transplanted tumors in human Hep-2 cell tumor-bearing BALB/c mice, and may have therapeutical effect on laryngeal cancer.

Antitumor efficacy of extracellular complexes with gadolinium in Binary Radiotherapy.

In this report the efficacy of extracellular pharmaceutical Gd-DTPA in Binary Radiotherapy was studied. The study was carried out in mice bearing transplantable adenocarcinoma Ca755 using X-ray based contrast enhanced radiotherapy as a practical implementation of Binary Radiotherapy. It was shown that intravenous administration of 0.3 ml of 0.5 M water solution of Gd-DTPA followed by X-irradiation at a dose of 10 Gy provides T/C%=10±3% and leads to complete tumor regression in 25% of mice.